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University of Gothenburg, Gothenburg, SwedenSee Editorial, pages 537–538Background and Aims: Approximately 95% of bile acids (BAs) correlated with reduced Bsep transcription, while Ntcp and
excreted into bile are reabsorbed in the gut and circulate back Cyp7a1 were induced. Importantly A4250 significantly reduced
to the liver for further biliary secretion. Therefore, pharmacolog-
ical inhibition of the ileal apical sodium-dependent BA trans-
porter (ASBT/SLC10A2) may protect against BA-mediated
cholestatic liver and bile duct injury.
Methods: Eight week oldMdr2/ (Abcb4/) mice (model of cho-
lestatic liver injury and sclerosing cholangitis) received either a
diet supplemented with A4250 (0.01% w/w) – a highly potent
and selective ASBT inhibitor – or a chow diet. Liver injury was
assessed biochemically and histologically after 4 weeks of
A4250 treatment. Expression profiles of genes involved in BA
homeostasis, inflammation and fibrosis were assessed via RT-
PCR from liver and ileum homogenates. Intestinal inflammation
was assessed by RNA expression profiling and immunohisto-
chemistry. Bile flow and composition, as well as biliary and fecal
BA profiles were analyzed after 1 week of ASBT inhibitor feeding.
Results: A4250 improved sclerosing cholangitis in Mdr2/ mice
and significantly reduced serum alanine aminotransferase, alka-
line phosphatase and BAs levels, hepatic expression of pro-
inflammatory (Tnf-a, Vcam1, Mcp-1) and pro-fibrogenic (Col1a1,
Col1a2) genes and bile duct proliferation (mRNA and immunohis-
tochemistry for cytokeratin 19 (CK19)). Furthermore, A4250 sig-
nificantly reduced bile flow and biliary BA output, whichJournal of Hepatology 20
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lipid secretion resulting in an increased HCO3/BA and PL/BA
ratio. In addition, A4250 profoundly increased fecal BA excretion
without causing diarrhea and altered BA pool composition,
resulting in diminished concentrations of primary BAs tauro-
b-muricholic acid and taurocholic acid.
Conclusions: Pharmacological ASBT inhibition attenuates chole-
static liver and bile duct injury by reducing biliary BA concentra-
tions in mice.
 2015 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
In the Mdr2//Abcb4/ mouse model of sclerosing cholangitis,
bile duct injury develops as a consequence of defective biliary
phospholipid (PL) secretion and subsequent increase of free
non-micellar and potentially toxic bile acid (BA) concentrations
in bile [1]. As a result, pericholangitis, ductular proliferation
and typical onion skin type periductal fibrosis develops sponta-
neously in this model [2], thereby reflecting central morphologi-
cal features of chronic cholangiopathies, such as primary
sclerosing cholangitis (PSC) [1,3]. Therapeutic options for chronic
cholestatic liver diseases and cholangiopathies, particularly such
as PSC are limited and low in efficacy [3]. To date, ursodeoxy-
cholic acid (UDCA) is the only approved treatment for cholestatic
liver disease [4]. However, its efficacy in patients with PSC and
cholestatic liver injury due to mutations in the MDR3 gene
(human orthologue of murineMdr2) is limited [5,6]. Since altered
bile composition is an important pathogenic factor for initiation16 vol. 64 j 674–681
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and/or progression of cholestatic liver and bile duct injury [7,8]
modulation of bile composition arises as an interesting strategy
for therapeutic interventions.
Following biliary secretion, BAs undergo enterohepatic
circulation, a process where the ileal brush border membrane
transporter, the apical sodium-dependent bile salt transporter
(ASBT/SLC10A2) [9], mediates the active re-uptake of up to 95%
of BAs from terminal ileum and their return back to liver, thus
playing an important role in regulating the rate of biliary BA
secretion. We, therefore, hypothesized that interruption of BA
enterohepatic circulation may markedly reduce biliary concen-
trations of potentially toxic BAs and exert beneficial therapeutic
effects on cholangitis and cholestasis. Hence, Mdr2/ mice as a
model of sclerosing cholangitis were treated with the selective
and potent ASBT inhibitor A4250. Our study demonstrates
that interruption of enterohepatic BA circulation via ASBT
inhibition improves cholestatic liver and bile duct injury in a
mouse model of sclerosing cholangitis, suggesting that ASBT
inhibitors may represent a novel and promising treatment for
cholangiopathies.Material and methods
Animals
Mdr2/ mice (FVB/N background) were obtained from Jackson Laboratory (Bar
Habor, ME) and housed in a 12 h light/dark house facility with water and stan-
dard chow diet (SSNIFF, Soest, Germany) ad libitum.
Feeding protocols
A4250 (a specific ASBT inhibitor) was synthesized by Albireo Pharma (41346
Gothenburg, Sweden). Eight week old male Mdr2/ mice received either control
diet or a diet supplemented with 0.01% (w/w) A4250 either for 4 weeks or for
1 week. The 4 week treatment protocol was used for biochemical, molecular
and histological data analysis, whereas the 1 week treated mice were subjected
to bile flow measurement. The experimental protocols were approved by the local
animal care and use committee according to the criteria outlined in the Guide for
the care and Use of Laboratory Animals prepared by the U.S. National Academy of
Science (National Institutes of Health publication 86-23, revised 1985).
Food intake, body weight/liver weight measurement
Food intake and body weight were controlled weekly. Liver weight (LW) to
body weight (BW) % ratio as well as spleen weight (SW) to BW % ratio was
calculated.
Routine serum biochemistry
Blood was collected retro-orbitally after 2 weeks and 4 weeks of experimental
feeding. Enzymatic assays were used to measure serum aspartate aminotrans-
ferase (AST), alanine aminotransferase (ALT) as well as alkaline phosphatase
(AP) and bilirubin (Roche Diagnostics, Mannheim, Germany), whereas serum BA
levels were measured with the Bile Acid Kit (Ecoline S+ from DiaSys Diagnostic
Systems GmbH, Holzheim, Germany) in a Hitachi 917 Analyzer (Boehringer Man-
nheim, Mannheim, Germany).
Histology
For conventional light microscopy, organs (liver, gallbladder and colon) were
fixed in 4% neutral buffered formaldehyde solution for 24 h and embedded in
paraffin. Sections were cut 4 lm thick and stained with Hematoxilin and Eosin
(H&E) or Sirius Red as described [2]. Quantification of Sirius Red positive area
was performed using Image J program (v1.47v; National Institute of Health,
Bethesda, Maryland).Journal of Hepatology 201Immunohistochemistry
Detection of the cholangiocyte marker cytokeratin (CK) 19 was performed with
immunohistochemistry (IHC) as described [10]. To assess colonic inflammation,
cell proliferation and glucagon-like peptide 1 (GLP-1) expression, colon slices
were stained immunohistochemically for the macrophage marker F4/80, the pro-
liferation marker Ki67 and GLP-1 in addition to conventional H&E staining after
1 week of chow or A4250 feeding. Cell proliferation and macrophage infiltration
was quantified by ImageJ software (v1.47v; National Institute of Health).
Hepatic hydroxyproline content
To quantify liver fibrosis, hepatic hydroxyproline was measured from a standard-
ized liver lobe as described previously [11].
Measurement of bile flow and composition
Bile flow and biliary BA profile measurements were performed as described pre-
viously [2]. Experimental feeding was initiated in 8 weeks old maleMdr2/mice.
After 7 days of feeding the common bile duct was ligated and the gallbladder was
cannulated. After a 10 min equilibration period, bile was collected in pre-
weighted tubes for 30 min. Bile flow was determined gravimetrically and normal-
ized to LW. Biliary PL concentration were measured by Wako Phospholipid Kit
and biliary bicarbonate concentrations were measured in a routine laboratory.
Bile acid profiling by ultra-performance liquid chromatography tandem mass-
spectrometry
Profiles of murine primary and secondary unconjugated and conjugated C24-BAs
in serum (30 ll), bile (15 ll, diluted by 1 ml MeOH), and feces were analyzed as
published previously [12] on an Applied Biosystems AB SCIEX QTRAP 5500 plat-
form. Taurine-conjugated tetrahydroxylated BAs were identified from their
molecular anion m/z 530, and quantified in relation to d4-taurocholic acid
(D4-TCA).
Messenger RNA analysis and Polymerase Chain Reaction (PCR)
RNA isolation from liver and intestine, complementary DNA synthesis and real-
time PCR were performed as described previously [13]. Oligonucleotide
sequences are available upon request.
Western blot analysis
Protein expression was quantified as described previously [14].
Statistical analysis
Results were evaluated using SPSS V.14.0. Statistical analysis was performed
using one-way analysis of variance test followed by student t test. Data were
reported as means of 5 animals per group ± SD. A p value 60.05 was considered
significant.Results
Selective ASBT inhibitor A4250 improves cholestatic liver and bile
duct injury in Mdr2/ mice
A4250 was well tolerated in Mdr2/ mice and had no impact on
animal behavior or body weight after short- or long-term feeding
(1 and 4 weeks, respectively; data not shown). In our study we
focused on potential changes of cholestatic liver and biliary injury
in Mdr2/ mice at 8 weeks of age, a time point when bile duct
injury is fully established with pronounced cholestasis [11] in
these mice. As determined by liver histology, A4250 ameliorated
bile duct injury with pericholangitis and onion skin type fibrosis6 vol. 64 j 674–681 675
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Fig. 2. A4250 reduces bile duct proliferation in Mdr2/ mice. (A) Represen-
tative immunohistochemical stainings for cholangiocyte cytoskeleton marker
cytokeratin 19 (CK19) (brown) demonstrate reduced number of proliferating bile
ducts after A4250 feeding. Portal tract-centered photomicrograph reflects
decreased inflammation and onion skin type fibrotic tissue around the large bile
duct of A4250-treated Mdr2/ mouse (upper panel). Photomicrographs of the
liver lobule reflect decreased periportal lobular extensions of ductular structures
after A4250 feeding (lower panel). (B) Computerized analysis (ImageJ) of
immunohistochemistry reflects reduced CK19 expression in A4250 treated
animals. (C) CK19 mRNA expression is significantly reduced by A4250 in
Mdr2/ mice. Gene expression levels are normalized to 36b4 housekeeping gene
expression and mean values in chow-fed Mdr2/ mice are set as 1. Results are
presented as means ± SD for n = 5 animals per group. ⁄p <0.05 A4250-fed Mdr2/
mice vs. chow-fed Mdr2/ mice.
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Fig. 1. A4250 improves sclerosing cholangitis and cholestatic liver injury in
Mdr2/ mice. (A) Representative liver histology of 12 weeks old chow-fed
Mdr2/ mice show typical onion skin type fibrosis. Liver histology of A4250-
treated, age-matched Mdr2/ mouse shows improved pericholangitis and onion
skin fibrosis after 4 weeks of A4250 feeding. (B, C and D) Serum biochemical
parameters of hepatocellular injury (ALT) and cholestasis (AP and BAs) inMdr2/
mice after 2 and 4 weeks of either chow or A4250-supplemented diet feeding.
Mdr2/mice show increased serum ALT, AP and BA levels, which progresses with
age. Compared with chow-fed controls (open bars), serum ALT levels decrease at
2 weeks and AP and BA levels after 4 weeks of A4250 feeding in Mdr2/ mice
(blue bars). (E) Compared with age-matched littermates, LW/BW (%) and SW/BW
(%) are significantly lower inMdr2/ mice after 4 weeks of A4250 feeding. Values
are means ± SD for n = 5 animals per group. ⁄p <0.05 A4250-fedMdr2/ vs. chow-
fed Mdr2/ mice. ALT, alanine aminotransferase; AP, alkaline phosphatase; BAs,
bile acids; bd, bile duct; BW, body weight; LW, liver weight; SW, spleen weight.
Research ArticleinMdr2/mice after 4 weeks of feeding (Fig. 1A). Notably, serum
ALT as marker of hepatocellular injury was significantly
decreased already after 2 weeks (Fig. 1B), whereas serum
markers of cholestasis (AP and BA) were significantly decreased
after 4 weeks of A4250 feeding in Mdr2/ mice (Fig. 1C and D).
This indicates that longer treatment is required to observe the
full impact on biliary injury. In line with serum liver enzymes
and BAs, serum bilirubin also slightly but significantly
decreased in Mdr2/ mice after A4250 feeding (0.085 ± 0.0 vs.
0.16 ± 0.1 mg/dl). Interestingly, serum triglyceride levels
remained unchanged, while serum cholesterol increased in
Mdr2/ mice after dietary A4250 supplementation (Supplemen-
tary Fig. 1). In line with the histological and biochemical findings,
liver LW/BW and SW/BW% ratios were significantly decreased in
Mdr2/ mice after A4250 treatment (Fig. 1E), reflecting its over-
all beneficial effects on liver injury. Furthermore, A4250 signifi-
cantly decreased proliferation of bile ducts (Fig. 2A) as
determined by CK19 IHC staining and quantification (Fig. 2B) as
well as assessment of mRNA expression (Fig. 2C). Altogether,
these findings established a beneficial role of ASBT inhibition
on cholestatic liver and bile duct injury in a mouse model of scle-
rosing cholangitis.
Hepatic inflammation and periductal fibrosis are reduced by A4250
in Mdr2/ mice
Since ongoing inflammation and reactive proliferation of bile
ducts in cholangiopathies are associated with development of bil-676 Journal of Hepatology 201iary fibrosis [3]. We next measured mRNA expression of Tnf-a,
Mcp-1 and Vcam-1, the main pro-inflammatory cytokines
involved in the pathogenesis of liver injury in Mdr2/ mice
[11] (Fig. 3A) in addition to expression of biliary fibrosis
markers such as Col1a1 and Col1a2 (Fig. 3B). Interestingly, tran-
scription of pro-fibrogenic genes such as Col1a1 and Col1a2
was profoundly reduced in A4250-treated mice (Fig. 3B). Con-
versely, hepatic hydroxyproline content and a-SMA protein
levels did not differ between the groups (Fig. 3C, 3D). In line with
inhibited expression of pro-inflammatory cytokines and pro-
fibrogenic genes, quantification of Sirius Red staining revealed
significantly reduced peribiliary fibrosis and a tendency towards
a reduction of overall fibrosis (Fig. 3E, F). Taken together,
these data suggest an anti-inflammatory and moderate anti-
fibrotic effect of A4250 over a 4 week treatment course in
Mdr2/ mice.A4250 significantly alters bile acid homeostasis in Mdr2/ mice
Importantly, gene expression of Asbt as well as basolateral BA
transporter Ost-a and Ost-b in the ileum of Mdr2/ mice
remained unchanged after A4250 feeding, whereas expression
of Fgf15, an important intestinal regulator of BA synthesis [15]
and target of intracellular BA sensor FXR [16,17] was profoundly
reduced (Fig. 4A), thereby confirming efficient inhibition of ileal
BA uptake. In line, A4250 feeding resulted in 3-fold enhanced
transcription of the rate limiting enzyme for BA synthesis choles-
terol 7 alpha-hydroxylase (Cyp7a1) and sinusoidal BA uptake
transporter Ntcp in liver, while expression of the canalicular BA
export pump Bsep was reduced (Fig. 4B). In addition, A4250
reduced gene expression of BA detoxifying enzymes Cyp3a11,
Ugt1a1 and Ugt2b5 and sinusoidal export transporter Mrp3 with-
out significant alterations of sinusoidal exportersMrp4, Ost-a and
Ost-b (Fig. 4B). Collectively, these findings reflect decreased hep-
atocellular BA load and compensatory changes of hepatic BA
homeostasis.6 vol. 64 j 674–681
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Fig. 3. Hepatic inflammation and fibrosis is decreased in Mdr2/ mice after
A4250 feeding. (A) mRNA expression levels of pro-inflammatory markers Tnfa,
Mcp1 and Vcam-1 were reduced by A4250 (blue bars) compared to chow-fed
controls (open bars). (B) A4250 significantly inhibits transcription of hepatic pro-
fibrogenic markers Col1a1 and Col1a2. Expression levels are normalized to 36b4
gene expression and mean expression in chow-fed Mdr2/ mice is set as 1. (C)
Hepatic hydroxyproline content remained unchanged between the chow- and
A4250-fed Mdr2/ mice. (D) a-SMA western blot does not show differences
between untreated and treated Mdr2/ mice (E and F) Representative Sirius red
staining and quantifications demonstrate typical onion skin-type periductal
fibrosis (E) and without pronounced changes in biliary septal fibrosis (F) in both
groups. (10 magnification) ⁄p <0.05 A4250-fed Mdr2/ vs. chow-fed Mdr2/
mice.
JOURNAL OF HEPATOLOGYASBT inhibition reduces biliary BA output and modifies biliary BA
composition
A4250 significantly reduced bile flow (Fig. 5A), which was associ-
ated with significant reductions of biliary BA concentrations and
output (Fig. 5B, C). Furthermore, A4250 significantly altered bil-
iary BA composition by reducing concentrations of primary BAs
tauro-b-muricholic acid (TbMCA) and taurocholic acid (TCA)
(Fig. 5D). In contrast, concentrations of the secondary BAs tau-
rodeoxycholic acid (TDCA) and taurohyodeoxycholic acid
(THDCA) were increased, whereas tauro-x-muricholic acid
(TxMCA) and tauroursodeoxycholic acid (TUDCA) were reduced
(Fig. 5E). Of note, unconjugated BAs were not found in bile of
chow or A4250-fed mice. Total fecal BA levels were markedly
increased in mice subjected to A4250 feeding (Fig. 5F). Of note,Journal of Hepatology 201anions suggesting the presence of sulphated BAs were not found
in feces. Importantly, contrasting diminished BA output, biliary
concentrations as well as output of protective HCO3 did not dif-
fer between the A4250-fed and chow-fed mice (Fig. 5B, C),
whereas relative output of HCO3 and of PLs was significantly
increased in A4250-fed Mdr2/ mice as demonstrated by
increased ratios of HCO3/BA and PL/BA (Fig. 5B). Since non-
micellar bound free BAs are believed to trigger cholangiopathy
in Mdr2/ mice [2,9,11], significant reduction of biliary BA out-
put with simultaneous increase of HCO3 proportion may
represent an important protective mechanism in toxic bile-
mediated liver injury.A4250 treatment does not promote diarrhea or gut inflammation in
Mdr2/ mice
Despite markedly increased total fecal BA levels (Fig. 5F) mice did
not develop diarrhea as determined by assessing stool quantity
and consistency. As such, we observed no difference in stool
weight between control group and A4250 fed mice. (1.30 g stool
per day in control mice vs. 1.38 g stool in A4250 fed mice). We
also addressed whether A4250 promotes colon inflammation.
Importantly, conventional histology showed no differences in
structure as well as inflammatory cell infiltration of the colonic
wall between chow and A4250-fed Mdr2/ mice (Fig. 6A). Fur-
thermore, IHC staining for the macrophage marker F4/80 (data
not shown) and the proliferation marker Ki67 (Fig. 6B, E) showed
no significant differences between experimental groups. In line
with these findings, transcription of pro-inflammatory cytokine
Tnf-a remained unchanged in the ileum of A4250-treated
Mdr2/ mice (Fig. 6D). Since GLP-1 released from entero-
endocrine cells in response to increased intestinal BA concentra-
tions may have direct protective effects on cholangiocytes [18],
we next addressed whether GLP-1-mediated gut-liver signaling
may contribute to A4250-mediated beneficial effects in
cholestasis. Notably, GLP-1 IHC did not show differences between
control and A4250 fed animals whereas ileal mRNA expression
of pre-glucagon was reduced in A4250-fed Mdr2/ mice
(Fig. 6C and F), indicating that this mechanism is rather unlikely
to contribute to A4250-mediated protection from cholestatic
liver and bile duct injury.A4250 reduces gallbladder size
Since bile homeostasis plays a critical role in gallbladder physiol-
ogy, we also studied the impact of reduced bile flow and biliary
BA output on gallbladder morphology. Interestingly, thickness
of gallbladder wall was increased in A4250-fed Mdr2/ mice
through increased thickness of muscularis propria and number
of mucosal folds (Supplementary Fig. 2A, B). Importantly, no
increase of inflammatory cell infiltration as reflected by F4/80
staining was detected in lamina propria, muscularis propria or
epithelium (Supplementary Fig. 2C), thereby excluding an
inflammation-mediated mechanism of gallbladder wall thicken-
ing. Since Fgf15 stimulates gallbladder filling through counteract-
ing cholecystokinin [19], increased gallbladder wall thickness
may reflect reduced Fgf15 signaling resulting in a contracted gall-
bladder in A4250-fed Mdr2/ mice. Importantly, gallbladders of
Mdr2/ mice treated with A4250 were not filled with sediments
or stones.6 vol. 64 j 674–681 677
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Our study demonstrates that the novel highly potent and selec-
tive ASBT inhibitor A4250 decreases cholestatic liver and bile
duct injury in theMdr2/ mouse model of sclerosing cholangitis.
After 4 weeks of A4250 treatment, liver histology showed pro-
foundly reduced bile duct injury, pericholangitis and periductal
fibrosis (Fig. 1A). Improvement of cholestatic liver injury was fur-
ther evidenced by reduced serum liver enzymes and BA levels
(Fig. 1A–C). At the same time pro-inflammatory mediators as well
as bile duct proliferation (both driving biliary fibrosis) [20] were
significantly reduced (Figs. 2, 3A). Furthermore, Sirius Red
staining and mRNA levels of fibrotic markers (Fig. 3B, E, F) indi-
cate a decrease of fibrosis in Mdr2/ mice treated with the ASBT
inhibitor. The finding that hydroxyproline levels were only ten-
dentially reduced in A4250 treated mice could be explained by
the fact that all hydroxyproline groups (including those from
fragmented collagen) [21] are detected via the photometric mea-
surement, while Sirius Red staining reflects largely the fibrillary
collagen deposits in the tissue (type I and III) [21]. Collectively,
our data demonstrate that inhibition of ileal BA absorption may
have important implications for the treatment of cholan-
giopathies and cholestatic liver injury.
This improvement in morphological and biochemical features
of cholangiopathy of Mdr2/ mice may be explained by the
reduction in overall biliary BA output following inhibition of
ASBT and subsequent changes in the biliary BA composition
(Fig. 5). Interestingly, elevated BA de novo synthesis (reflected
by increased Cyp7a1 expression) (Fig. 4B) cannot compensate
for the reduction in BA re-uptake. Since HCO3 output as well
as PL secretion were not changed in response to ASBT inhibitor
feeding, the PL/BA ratio (which is critical in micelle formation
[22]) as well as the HCO3/BA ratio (important for the protective
function of the bicarbonate umbrella [8]) were clearly elevated in
A4250 fedMdr2/ mice (Fig. 5B). Thus, A4250 treatment reduces
biliary toxicity in this model by at least two mechanisms. First,
the increased PL/BA ratio reduces the concentration of toxic BA
monomers. Second, the relative increase of HCO3 (the so called
bicarbonate umbrella [7,8]) maintains an alkaline milieu which
reduces protonation of potentially toxic BA. Notably, other
mechanisms such as cholehepatic shunting [23] as well as active
induction of ductular HCO3 secretion mediated through mem-
brane BA receptor TGR5 may play a critical role in regulating678 Journal of Hepatology 201biliary HCO3 secretion [24], but do not appear to contribute to
the improvement of bile duct injury by A4250 treatment.
Measurement of fecal BAs revealed a considerable increase of
BA excretion in A4250 fed animals. BA malabsorption is known to
cause diarrhea in humans [25–28]. A recent phase I study
reported that A4250 was well tolerated and dose-dependent
diarrhea was observed in only 21% of normal volunteers receiving
A4250 [29]. Consistent with observations in mice lacking ASBT
[30], pharmacological interruption of ileal BA reabsorption by
A4250 was accompanied by regular stool behavior without signs
of diarrhea in Mdr2/ mice. Importantly, A4250 treated mice
also showed no evidence of colonic inflammation. Differences
in the incidence of diarrhea between mice and humans may
relate to different colonic BA and microbiota composition; e.g.
in mice the fecal amounts of chenodeoxycholic acid (considered
to be the most potent secretagogue in humans [31,32]) are neg-
ligible. Certainly the incidence and severity of diarrhea under
A4250 treatment in patients with PSC (and other cholestatic liver
diseases) needs to be addressed in future clinical studies.
BA sequestrants represent another approach to interrupt the
enterohepatic circulation of BA and are cheap and readily avail-
able drugs to inhibit ileal BA absorption. However, they have
potential side effects such as constipation, bloating, elevated
triglycerides and bad taste and may cause deficiencies of fat sol-
uble vitamins [33]. Interestingly, as proof of principle, cholestyra-
mine has been reported to improve serum parameters of
cholestasis in addition to symptoms in PSC [34]. However, cole-
sevelam was not proven to be of sufficient clinical efficacy in
cholestasis and showed substantial side effects (such as constipa-
tion, flatulence, indigestion and nausea) and poor tolerability in
humans [35].
We noted a reduction in gallbladder size with increased wall
thickness in mice treated with A4250 (Supplementary Fig. 2).
Increased gallbladder emptying has been demonstrated after
cholestyramine administration [36,37]. Furthermore, recent find-
ings also demonstrated increased gallbladder contraction when
FGF15/19 was absent or reduced [19]. Therefore, increased wall
thickness and number of mucosal folds may most likely reflect
the non-dispensed state of gallbladder due to abolished Fgf15 sig-
naling as a result of ASBT inhibition.
In addition to changes in bile composition attenuating toxicity
of bile, other intestine-mediated mechanisms may also con-
tribute to A4250-mediated beneficial effects. BAs are key-6 vol. 64 j 674–681
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JOURNAL OF HEPATOLOGYregulators of gut microbiota. Dysbiosis has recently been linked
to pathogenesis of cholangiopathies such as PSC [38]. Although,
potential changes in microbiota composition inMdr2/mice still
remain to be determined, it is attractive to speculate that block-
age of ileal BA transport by A4250 could result in microbiota
shifts contributing to part of the therapeutic effects. Therefore,
further studies may be justified to explore the impact of ASBT
inhibition on changes of gut microbiota in liver disease.
It may be hypothesised that increased exposure of colonic
mucosa to BA could alter GLP-1 expression. Entero-endocrine
L-cells play an important role in regulating glucose metabolism
through GLP-1 [39]. Importantly, BA sequestrants induce GLP-1
precursor pro-glucagon expression and GLP-1 release in a
TGR5-dependent manner [39]. Given the fact that A4250 pro-
motes increased BA delivery to the distal parts of gut, secondary
BA could induce GLP-1 release through direct and more potentJournal of Hepatology 201TGR5 activation [39]. Apart from metabolic effects, GLP-1
released from the intestine may enter the liver via portal blood
and bind to receptors on cholangiocytes and protect cholangio-
cytes from BA induced injury/stress by modulating the cholangio-
cyte adaptive response to cholestasis [40]. Therefore, exendin-4, a
GLP-1 receptor agonist, protects cholangiocytes from apoptosis
[18,40,41]. However, our data showed unchanged immunostain-
ing of GLP-1 in colon and even reduced mRNA expression of preg-
lucagon (the precursor of GLP-1) in the ileum (Fig. 6E) of A4250
treated mice, consistent with recent findings demonstrating that
GLP-1 release is predominantly induced by systemic BAs acting
on the basolateral site of the enterocytes [42]. Moreover, it has
recently been demonstrated that increased FXR activity in
L-cells may even reduce GLP-1 secretion [43].
Our study provided a detailed analysis of intestinal expression
of BA-regulated genes such as FGF15/19 and GLP-1 expanding
parallel studies on other ASBT inhibitors such as SC-435 [44].
The effects of A4250 on intestinal FXR-signaling and FGF15/19
are in apparent contrast to other promising strategies for treat-
ment of cholangiopathies such as FXR ligands [45]. Fibrates also
reduce BA synthesis (via PPARa mediated downregulation of
Cyp7a1 and Cyp27) and biliary output despite reduction of FGF-
15/19 [46]. One potential benefit for usage of ASBT inhibitors as
therapy for cholestatic liver disease may be the reduction of
FGF15 expression seen in our A4250 fed animals (Fig. 4A).
FGF15/19 is suggested to have potential carcinogenic properties
and effects on cholangio-carcinogenesis have to be carefully6 vol. 64 j 674–681 679
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considered [47]. It is attractive to speculate, that a combination of
such different therapeutic approaches (especially cholehepatic
drugs such as conjugation-resistant norUDCA (not undergoing
an enterohepatic circulation) [11]) may have complementary
therapeutic mechanisms of action.
In conclusion, our study demonstrates that inhibition of ASBT
with A4250, a novel, highly potent ASBT inhibitor, reduces bile
toxicity by decreasing biliary BA output and concentration,
resulting in an improvement of sclerosing cholangitis in Mdr2/
mice. Therefore, our results suggest that inhibition of ileal BA
transporter ASBT may open new avenues for pharmacological
treatments of PSC patients.Financial support
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